DexCom, Inc. (NASDAQ:DXCM) Receives $86.30 Average Target Price from Analysts

Shares of DexCom, Inc. (NASDAQ:DXCM) have been given a consensus rating of “Moderate Buy” by the twenty-seven brokerages that are covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, four have given a hold recommendation, nineteen have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $86.3043.

Several equities analysts recently issued reports on DXCM shares. Stifel Nicolaus began coverage on DexCom in a research report on Tuesday, October 21st. They issued a “buy” rating and a $85.00 target price on the stock. Robert W. Baird set a $82.00 price target on DexCom in a research note on Friday, October 31st. UBS Group cut their price objective on DexCom from $106.00 to $95.00 and set a “buy” rating on the stock in a report on Monday, November 3rd. JPMorgan Chase & Co. reduced their price objective on DexCom from $90.00 to $75.00 and set a “neutral” rating for the company in a research note on Friday, October 31st. Finally, Argus dropped their target price on DexCom from $100.00 to $90.00 and set a “buy” rating on the stock in a research report on Friday, November 7th.

Insider Buying and Selling at DexCom

In other news, Director Bridgette P. Heller sold 1,012 shares of the company’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $58.07, for a total value of $58,766.84. Following the sale, the director directly owned 27,031 shares of the company’s stock, valued at $1,569,690.17. This represents a 3.61% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Richard Alexander Collins sold 2,906 shares of the firm’s stock in a transaction on Friday, November 14th. The stock was sold at an average price of $59.05, for a total transaction of $171,599.30. Following the transaction, the director directly owned 35,088 shares of the company’s stock, valued at approximately $2,071,946.40. This trade represents a 7.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 7,866 shares of company stock worth $448,177. Company insiders own 0.32% of the company’s stock.

Institutional Trading of DexCom

A number of hedge funds have recently added to or reduced their stakes in DXCM. Brighton Jones LLC lifted its stake in DexCom by 257.7% in the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock valued at $1,290,000 after buying an additional 11,946 shares in the last quarter. Integrated Wealth Concepts LLC raised its holdings in shares of DexCom by 6.3% during the first quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock valued at $227,000 after acquiring an additional 196 shares during the last quarter. Empowered Funds LLC raised its holdings in shares of DexCom by 5.4% during the first quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company’s stock valued at $577,000 after acquiring an additional 436 shares during the last quarter. Focus Partners Wealth lifted its position in shares of DexCom by 13.2% in the first quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company’s stock valued at $493,000 after acquiring an additional 841 shares in the last quarter. Finally, MassMutual Private Wealth & Trust FSB boosted its stake in shares of DexCom by 23.9% in the second quarter. MassMutual Private Wealth & Trust FSB now owns 1,125 shares of the medical device company’s stock worth $98,000 after acquiring an additional 217 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Stock Performance

Shares of DexCom stock opened at $70.73 on Friday. The company has a 50 day moving average price of $65.58 and a 200 day moving average price of $71.29. The firm has a market capitalization of $27.59 billion, a P/E ratio of 39.29, a PEG ratio of 1.25 and a beta of 1.48. The company has a quick ratio of 1.38, a current ratio of 1.56 and a debt-to-equity ratio of 0.45. DexCom has a 52 week low of $54.11 and a 52 week high of $93.25.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.04. The company had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.18 billion. DexCom had a net margin of 15.96% and a return on equity of 30.65%. DexCom’s revenue was up 21.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.45 EPS. Sell-side analysts expect that DexCom will post 2.03 EPS for the current year.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.